Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Cytosorbents (CTSO) Receivables - Other (2017 - 2025)

Cytosorbents' Receivables - Other history spans 9 years, with the latest figure at $7.1 million for Q4 2025.

  • Quarterly results put Receivables - Other at $7.1 million for Q4 2025, up 27.23% from a year ago — trailing twelve months through Dec 2025 was $7.1 million (up 27.23% YoY), and the annual figure for FY2025 was $7.1 million, up 27.23%.
  • Receivables - Other for Q4 2025 was $7.1 million at Cytosorbents, up from $6.0 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $7.1 million in Q4 2025 to a low of $2.8 million in Q1 2021.
  • The 5-year median for Receivables - Other is $4.6 million (2023), against an average of $4.7 million.
  • Peak annual rise in Receivables - Other hit 62.34% in 2021, while the deepest fall reached 0.13% in 2021.
  • Year by year, Receivables - Other stood at $3.0 million in 2021, then grew by 27.39% to $3.8 million in 2022, then soared by 38.65% to $5.3 million in 2023, then increased by 5.66% to $5.6 million in 2024, then grew by 27.23% to $7.1 million in 2025.
  • According to Business Quant data, Receivables - Other over the past three periods came in at $7.1 million, $6.0 million, and $6.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.